BioLineRx In-Licenses Novel Technology from Ben-Gurion University for the Treatment of Heart Attack Victims.JERUSALEM -- Company Adds Novel Treatment of Cardiac Tissue Damage to Diverse Drug Pipeline BioLineRx Ltd., Israel's leading specialized drug development company, today announced that it has signed an in-license agreement for the development of BL-1040, an injectible scaffold that reduces cardiac damage after heart attack. The worldwide exclusive license agreement was signed with Ben-Gurion University through its business company BGN BGN In currencies, this is the abbreviation for the Bulgarian Lev. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. Technologies. BioLineRx plans to develop the project through BioLine Innovations Jerusalem and to submit the project for funding by the Israeli Office of the Chief Scientist Office of the Chief Scientist may refer to:
According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. University President Prof. Avishay Braverman Avishay Braverman (Hebrew: אבישי ברוורמן , "The University sees its mission to use science and technology to bring employment - particularly in the hi-tech fields - to the periphery. We continue to be leaders in research and development despite the very serious cuts to our R&D budget." The novel material, developed by Prof. Smadar Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. and Prof. Jonathan Leor from the Department of Biotech and Biomedical Engineering Biomedical engineering An interdisciplinary field in which the principles, laws, and techniques of engineering, physics, chemistry, and other physical sciences are applied to facilitate progress in medicine, biology, and other life sciences. at Ben-Gurion University in Beer Sheva Sheva (shē`və), in the Bible. 1 Son of Caleb. 2 David's scribe: see Shavsha. is a biodegradable polymer that is injected directly into the area damaged by the heart attack. Within minutes, the material intercalates between the cells and fibers of the heart and rapidly forms a scaffold. This scaffold enhances the mechanical strength of the heart muscle during recovery and repair, reduces the size of the scar after the heart attack, and may stimulate the growth of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. and encourage cardiac regeneration. In experimental heart attack models, the polymer has been shown to improve outcome, resulting in reduced cardiac dysfunction and reduced mortality. "This agreement continues our commitment to building a strong diverse pipeline of novel treatments for unmet medical needs," said Dr. Morris C. Laster, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BioLineRx. "We believe this new technology developed by Ben-Gurion researchers represents a breakthrough for the treatment of patients that have undergone heart attacks by regenerating cardiac tissue." Netta Cohen, CEO of BGN Technologies, added: "Ben-Gurion University prides itself on scientific research that holds the promise of commercialization. This agreement with BioLineRx brings us a step closer to realizing the great potential of this innovative research for saving lives." Cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease is one of the leading causes of death in the western world. Each year over a million Americans and a larger number of people worldwide experience heart attack or heart failure. The projected market for treating new cases exceeds $1 billion in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. alone. About BioLineRx, Ltd. Founded in 2003 by leaders in the Israeli life-sciences sector, BioLineRx is committed to bridging the gap between innovative R&D and the global pharmaceutical industry with proprietary ethical drug products. BioLineRx is focused on advancing projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx enriches the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. For more information, visit www.biolinerx.com. About BGN Technologies Ltd. BGN, the business company of Ben-Gurion University serves as the link between industry and academic research. BGN assists the university and its faculty to "translate" their inventions and academic results into commercially valuable products. BGN offers the industry inventions in the fields of pharmaceuticals and drug delivery, biotechnology and medical devices, information technology, security, electro-optics, nanotechnologies, chemical processes, agro-technology, environment and energy. For more information, visit www.bgu.ac.il/bgn. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion